What Women's Health Foundry is
Women's Health Foundry is specialist infrastructure being developed to help selected women's health innovations move from research toward de-risked, investment-ready ventures, with stage-appropriate support across evidence sequencing, venture milestones, and ecosystem connections.
It is built for credibility with founders, researchers, universities, clinicians, industry, investors, and government-adjacent stakeholders: serious, institutional, high-trust, and operator-led.
Leadership
Who runs the Foundry
An independent Board chaired by Sue MacLeman with Non-Executive Directors Professor Victoria Cogger and Liza Noonan, supported by a day-to-day operator team drawn from Proto Axiom's investment, science, and operations capability.
Chair of the Board
Sue MacLeman
Inaugural Chair of the Board
Sue MacLeman brings more than thirty years at the centre of Australia’s life sciences industry — senior executive roles at Amgen, Bristol-Myers Squibb, and Mesoblast, inaugural CEO and then Chair of MTPConnect, and multiple ASX, AIM, and NASDAQ board directorships. She currently serves as Chair of Medicines Australia, the peak body for the country’s innovative medicines industry, and is a Fellow of the Australian Academy of Technology and Engineering and a Graduate of the Australian Institute of Company Directors. Her appointment as inaugural Chair of the Board grounds Women’s Health Foundry in a leader with deep industry standing and a long record of translating Australian science.
Non-Executive Director
Professor Victoria Cogger
Non-Executive Director
Professor Victoria Cogger is an international research leader in ageing liver biology and targeted drug delivery, with two decades translating Australian university science into clinical and commercial impact. She is the inaugural Executive Director of the Sydney Biomedical Accelerator — the A$780 million partnership between the University of Sydney, Sydney Local Health District, and the NSW Government opening in 2028 — and was most recently Director of the ANZAC Research Institute. A Professor in the Faculty of Medicine and Health at the University of Sydney, she co-founded EndoAxiom, whose oral insulin therapy has progressed to Phase 1 clinical trials. Her appointment as Non-Executive Director grounds Women’s Health Foundry in a leader operating at the interface of academia, health systems, and translational science.
Non-Executive Director
Liza Noonan
Non-Executive Director
Liza Noonan is Chief Executive Officer of Cicada Innovations, Australia’s home for deep tech, bringing more than two decades of experience at the intersection of science, technology, and impact. Her career has been shaped by a commitment to building vibrant, inclusive, and globally connected innovation ecosystems. Before joining Cicada, Liza was Executive Director of Innovation at Investment NSW, where she helped shape programs that strengthen the state’s innovation landscape. She has also held senior roles at CSIRO, including leading the ON Accelerator, and was the founding CEO of Springboard Australia, supporting high-growth, women-led startups. Her appointment as Non-Executive Director brings Women’s Health Foundry a leader with deep capability across deep-tech commercialisation, government innovation policy, and ecosystem building for women-led ventures.
Operator team
Day-to-day platform delivery is led by an experienced operator team spanning investment, science, operations, and finance. The operator function is structurally separate from the Investment Review Committee and the Board, so that selection and fiduciary decisions remain independent.
Anthony Liveris
Chief Executive Officer
Builder-operator leading platform design, partner alignment, and capital strategy. Founder and CEO of Proto Axiom, with a decade creating university spinouts and running active incubation across the life sciences portfolio.
Hugh McGonagle
Chief Operating Officer
Responsible for operating model execution, milestone frameworks, and day-to-day platform operations. Oversees the 30-person operations team spanning investment, science, and company building.
Lindsay Wu, PhD
Chief Science Officer
Leads scientific diligence, evidence strategy, and research translation assessment across the portfolio. Academic background with deep expertise in translational science.
Tony Haddad
Operating Partner
Senior operating capability across venture building, commercial strategy, and portfolio company support. Bridges strategy and execution for platform ventures.
Laura Wimberger, PhD
Investment Associate
Investment analysis, deal diligence, and pipeline management. Scientific training combined with venture assessment capability.
Charlie Selth
Chief of Staff
Coordinates cross-functional execution, stakeholder engagement, and program delivery. Ensures operational alignment across platform workstreams.
John Roach
Head of Finance
Financial operations, fund administration, and reporting. Responsible for milestone-linked capital deployment and financial accountability to co-funders.
Richard Wang, PhD
Science Analyst
Scientific analysis and research assessment supporting diligence and evidence planning across therapeutic focus areas.
Marina Naidion
Business Manager
Business operations and administration supporting platform delivery and stakeholder coordination.
This is a representative selection. The full Proto Axiom team includes additional capability across legal, communications, and portfolio operations.
Proto Axiom
Proto Axiom is the builder-operator: it designs and runs the platform's operating model, milestone logic, partner alignment, and execution. Not passive capital or arm's-length sponsorship.
Women's Health Foundry uses a distinct public identity because institutions, clinicians, and investors need clarity on governance and independence. The platform is being developed with academic, clinical, consumer, industry, and investor partners.
Track record
Proto Axiom is a company creator: the first investor into university spinouts, taking large equity stakes and providing active incubation with a 30-person pharma-grade operations team. The Women's Health Foundry operating model draws directly on this infrastructure, with active institutional collaborations across leading Australian universities and research precincts.
8
Portfolio companies created from Australian university science
A$45M
Capital raised across 33 institutional and individual investors
4+
University partnerships (USyd, UNSW, Griffith, UoW)
30
Team members across investment, operations, and science
Governance
The Foundry operates under a three-committee structure — a Board with overall fiduciary responsibility, an independent Investment Review Committee for SME selection and funding decisions, and a Steering Committee for operational and scientific direction — with a written conflict-of-interest protocol and open selection processes.
Full detail on principles, committee remits, and recruitment is on the Governance page.
Disclaimer
Women's Health Foundry is a platform in development. Features, eligibility, timelines, and partnership models are subject to final settings and approvals. Nothing on this site constitutes medical, legal, tax, or investment advice or an offer to fund, partner with, or admit any person or organisation.